# DBV Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dbv-technologies

- Industry: Biotechnology
- Headquarters: Montrouge, France
- Website: www.dbv-technologies.com
- Total disclosed funding: $48M
- Latest round: Series C (Dec 16, 2010)
- Investors on record: 9

## About

DBV Technologies SA develops innovative epicutaneous immunotherapy solutions aimed at treating food allergies, particularly through its flagship product, the VIASKIN® patch, which enhances the immune response.DBV Technologies SA specializes in immunotherapy solutions for food allergies. Founded in 2002, the company is headquartered in Montrouge, France. Pierre-Yves Vannerom was instrumental in establishing the company. Recent funding activities include a Private Placement/Follow on in June 2022, raising a total of USD 194.00 mn, reflecting the company’s focus on research and development.DBV Technologies focuses on developing innovative epicutaneous immunotherapy solutions, primarily with its flagship product, the VIASKIN® patch. This technology aims to treat food allergies, particularly peanut and cow's milk allergies, by delivering small amounts of allergen through the skin, helping re-educate the immune system. The patch is designed for patients, including children and adolescents, facing severe allergic reactions, aiming to improve their quality of life and reduce the risk of anaphylaxis. The company is currently advancing its clinical research programs, which include comprehensive Phase 3 studies and completed trials in pediatric populations, primarily marketed in North America and Europe, where food allergies significantly impact children.DBV Technologies operates a B2B model, collaborating with healthcare organizations and research institutions to advance clinical trials and product development. In 2022, the company reported no revenue, with an EBITDA of USD -129,749,182.60, indicating the ongoing investment in research and regulatory processes for its investigational therapies. The revenues are expected to be generated through partnerships and grants, focusing on the future commercialization of its products, though specific pricing details remain undisclosed at this stage.DBV Technologies plans to launch new products using its research into the VIASKIN® patch and other therapies within the next few years. The company is targeting expansion into new geographic regions, particularly in Asia and Latin America, by 2025. The recent funding from its June 2022 round will support these initiatives, focusing on clinical trials and preparation for regulatory approvals, to enhance its market presence and facilitate the future commercialization of its products.

## Funding rounds

- Series C, Dec 16, 2010, $26M — Sofinnova Partners, Eiffel Investment Group, Lundbeckfond Ventures, Shire PLC, ALK-Abello, InnoBio Ventures
- Series B, Jan 22, 2009, $7.9M — Sofinnova Partners, ALK-Abello
- Series A, Jan 1, 2006, $15M — Apax Partners, Sofinnova Partners, Karista, Creagro
- Seed, Jan 1, 2003 — Karista, Creagro

## Investors

- Karista (https://capitalatlas.ai/funds/karista) — Seed, Series A
- Creagro — Seed, Series A
- Apax Partners (https://capitalatlas.ai/funds/apax-partners) — Series A
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B, Series C
- ALK-Abello — Series B, Series C
- Eiffel Investment Group (https://capitalatlas.ai/funds/eiffel-investment-group) — Series C
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series C
- Shire PLC — Series C
- InnoBio Ventures — Series C